ATLAS-2 (Completed)
A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects With a Recent Acute Coronary Syndrome
- Medicine
- rivaroxaban
- Population
- ASCVD
- Phase
- III
- Starting year
- 2009
- More information
- ClinicalTrials.gov